Utah Valley Hospital
- Type
- Teaching hospital
- Where
- Provo, UT
- Medicare CCN
- 460001
- Received
- $2,098,785 in 244 records, 2025 ($222,351 general, $1,876,433 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 35 | $222,351 |
| 2025 | Research payment | 209 | $1,876,433 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 209 | $1,876,433 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $124,027 |
| Grant | 8 | $47,650 |
| Royalty or License | 12 | $38,847 |
| Space rental or facility fees (teaching hospital only) | 5 | $8,650 |
| Consulting Fee | 1 | $1,737 |
| Debt forgiveness | 1 | $740 |
| Long term medical supply or device loan | 1 | $700 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | UROGEN PHARMA, INC. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JELMYTO Drug, UROTHELIAL CANCER | 2025 | |
| 2025-12-24 | United Therapeutics Corporation | $2,539 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,821 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,641 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-23 | APPLIED MEDICAL TECHNOLOGY INC | $2,753 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-12-17 | Grifols Therapeutics LLC | $21,700 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Thrombophilia Genetic Study in the USA: Thrombophilia occurrence study in patients admitted to a thrombosis clinic | 2025 |
| 2025-12-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,246 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-16 | United Therapeutics Corporation | $12,875 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-12-16 | Abbott Laboratories | $3,300 | Research payment | Cash or cash equivalent | PORTICO Device, Structural Heart | NCT04011722--Portico Next Generation Approval Study | 2025 |
| 2025-12-16 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | PORTICO Device, Structural Heart | NCT04011722--Portico Next Generation Approval Study | 2025 |
| 2025-12-16 | United Therapeutics Corporation | $1,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-12-16 | United Therapeutics Corporation | $100 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-12-12 | KARL STORZ Endoscopy-America | $11,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | KARL STORZ Endoscopy-America | $6,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,195 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-10 | United Therapeutics Corporation | $135 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-09 | Boston Scientific Corporation | $7,107 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-12-09 | Boston Scientific Corporation | $4,470 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-12-04 | Abbott Laboratories | $10,000 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE PRO Device, Diabetes Care | ISM2311001A--Continuous Glucose Monitoring System Comparison Study | 2025 |
| 2025-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,088 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-12-02 | United Therapeutics Corporation | $5,000 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-12-02 | Abbott Laboratories | $2,250 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-12-02 | United Therapeutics Corporation | $150 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-12-02 | Abbott Laboratories | $120 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-11-26 | Abbott Laboratories | $9,294 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $8,772 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $2,764 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $2,272 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $1,468 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-20 | Verastem, Inc. | $9,166 | Research payment | Cash or cash equivalent | RAMP 301 - GOG-3097 | 2025 | |
| 2025-11-19 | Abbott Laboratories | $672 | Research payment | Cash or cash equivalent | PORTICO Device, Structural Heart | NCT04011722--Portico Next Generation Approval Study | 2025 |
| 2025-11-17 | APPLIED MEDICAL TECHNOLOGY INC | $3,575 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-11-12 | United Therapeutics Corporation | $7,484 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $4,838 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $3,373 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $2,485 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-07 | Ipsen Bioscience Inc. | $1,806 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua | 2025 | |
| 2025-11-07 | United Therapeutics Corporation | $1,720 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | 2025 |
| 2025-11-07 | Ipsen Bioscience Inc. | $1,500 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua | 2025 | |
| 2025-11-06 | United Therapeutics Corporation | $6,993 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-11-06 | United Therapeutics Corporation | $576 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-11-06 | United Therapeutics Corporation | $28 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-11-05 | Intuitive Surgical Operations, Inc. | $21,029 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-11-05 | Abbott Laboratories | $16,174 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-11-04 | Boston Scientific Corporation | $100 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-11-03 | Abbott Laboratories | $21,695 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-10-29 | United Therapeutics Corporation | $10,000 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-10-29 | United Therapeutics Corporation | $2,600 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-10-29 | United Therapeutics Corporation | $1,500 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-10-29 | United Therapeutics Corporation | $500 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-10-29 | Novartis Pharmaceuticals Corporation | $402 | Research payment | In-kind items and services | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of | 2025 | |
| 2025-10-23 | United Therapeutics Corporation | $13,154 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-10-22 | United Therapeutics Corporation | $337 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-10-20 | Abbott Laboratories | $75 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04177394--MitraClip EXPAND G4 Study | 2025 |
| 2025-10-17 | National Marrow Donor Program | $11,495 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $195 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-13 | APPLIED MEDICAL TECHNOLOGY INC | $3,507 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-10-08 | United Therapeutics Corporation | $135 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-10-07 | Boston Scientific Corporation | $3,200 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-10-07 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | XIENCE SIERRA Device, Vascular | NCT03502811--The MitraClip EXPAND Study of the Next Generation of MitraClip Devices | 2025 |
| 2025-10-07 | Boston Scientific Corporation | $575 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-10-07 | United Therapeutics Corporation | $189 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-10-07 | Boston Scientific Corporation | $100 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-10-06 | United Therapeutics Corporation | $150 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-10-03 | GE HEALTHCARE | $1,737 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,761 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-30 | Iovance Biotherapeutics, Inc. | $2,000 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | IOV-EAP-402 | 2025 |
| 2025-09-30 | Novo Nordisk Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-25 | United Therapeutics Corporation | $4,500 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-09-25 | United Therapeutics Corporation | $665 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-09-25 | United Therapeutics Corporation | $517 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-09-23 | Boston Scientific Corporation | $3,488 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-09-15 | Novartis Pharmaceuticals Corporation | $14,005 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-09-15 | APPLIED MEDICAL TECHNOLOGY INC | $3,103 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-09-10 | United Therapeutics Corporation | $2,698 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $135 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-09-09 | Kite Pharma, Inc. | $650 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH P | 2025 |
| 2025-09-03 | United Therapeutics Corporation | $21,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | 2025 |
| 2025-09-03 | United Therapeutics Corporation | $4,200 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | 2025 |
| 2025-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,748 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-31 | Iovance Biotherapeutics, Inc. | $5,000 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | IOV-EAP-402 | 2025 |
| 2025-08-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-27 | Intuitive Surgical Operations, Inc. | $63,724 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-08-27 | United Therapeutics Corporation | $5,917 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-08-27 | United Therapeutics Corporation | $2,992 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-08-26 | Boston Scientific Corporation | $1,904 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-08-26 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-08-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,817 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-18 | Abbott Laboratories | $9,404 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-08-18 | APPLIED MEDICAL TECHNOLOGY INC | $3,074 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-08-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,950 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-14 | Ipsen Bioscience Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua | 2025 | |
| 2025-08-14 | Ipsen Bioscience Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua | 2025 | |
| 2025-08-13 | Abbott Laboratories | $17,007 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-08-13 | United Therapeutics Corporation | $540 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-08-04 | Abbott Laboratories | $19,937 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-08-04 | Abbott Laboratories | $290 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04177394--MitraClip EXPAND G4 Study | 2025 |
| 2025-08-04 | Alexion Pharmaceuticals, Inc. | $10 | Research payment | In-kind items and services | An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia | 2025 | |
| 2025-08-01 | United Therapeutics Corporation | $750 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-08-01 | United Therapeutics Corporation | $100 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-08-01 | United Therapeutics Corporation | $75 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-31 | United Therapeutics Corporation | $1,300 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-07-31 | United Therapeutics Corporation | $1,000 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-07-31 | United Therapeutics Corporation | $1,000 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-07-31 | United Therapeutics Corporation | $75 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,846 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-07-30 | Intuitive Surgical Operations, Inc. | $383 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-07-28 | BeOne Medicines Ltd. | $13,860 | Research payment | Cash or cash equivalent | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $133,567 | Research payment | Cash or cash equivalent | A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an | 2025 | |
| 2025-07-23 | National Marrow Donor Program | $10,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | United Therapeutics Corporation | $4,961 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-07-23 | United Therapeutics Corporation | $337 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-07-22 | Boston Scientific Corporation | $29,463 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-07-22 | United Therapeutics Corporation | $20,942 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-22 | Boston Scientific Corporation | $6,810 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-07-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,700 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-07-22 | Boston Scientific Corporation | $2,600 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-07-22 | Boston Scientific Corporation | $83 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-07-14 | APPLIED MEDICAL TECHNOLOGY INC | $3,348 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-07-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $830 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-07-10 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-07-08 | United Therapeutics Corporation | $4,811 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-07-08 | United Therapeutics Corporation | $3,110 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-07-07 | BeOne Medicines Ltd. | $6,125 | Research payment | Cash or cash equivalent | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac | 2025 | |
| 2025-07-04 | United Therapeutics Corporation | $9,920 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-07-03 | United Therapeutics Corporation | $2,500 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-03 | United Therapeutics Corporation | $750 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-03 | United Therapeutics Corporation | $189 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-03 | United Therapeutics Corporation | $75 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-02 | Intuitive Surgical Operations, Inc. | $1,150 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-07-01 | Abbott Laboratories | $80 | Research payment | In-kind items and services | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-06-27 | Intuitive Surgical Operations, Inc. | $742 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-06-25 | Abbott Laboratories | $9,626 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-06-25 | United Therapeutics Corporation | $2,992 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-06-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $790 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-06-17 | Boston Scientific Corporation | $8,879 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-06-17 | Boston Scientific Corporation | $83 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-06-16 | APPLIED MEDICAL TECHNOLOGY INC | $3,293 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-06-11 | United Therapeutics Corporation | $4,009 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-06-11 | United Therapeutics Corporation | $2,592 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-06-10 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04177394--MitraClip EXPAND G4 Study | 2025 |
| 2025-06-09 | Abbott Laboratories | $478 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04177394--MitraClip EXPAND G4 Study | 2025 |
| 2025-06-05 | Smith+Nephew, Inc. | $450 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PICO Device, Negative Pressure Wound Therapy | 2025 | |
| 2025-06-05 | Abbott Laboratories | $20 | Research payment | In-kind items and services | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-06-02 | United Therapeutics Corporation | $750 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-06-02 | United Therapeutics Corporation | $487 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-05-27 | Boston Scientific Corporation | $26,616 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-05-27 | Novartis Pharmaceuticals Corporation | $22,869 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | VictORION-INCLUSION: Evaluating INClisiran as a soLUtion to Improve LDL-C Management and cloSe Care Gaps in an Inclusive | 2025 |
| 2025-05-27 | KARL STORZ Endoscopy-America | $900 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | United Therapeutics Corporation | $7,242 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-05-21 | United Therapeutics Corporation | $2,085 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-19 | APPLIED MEDICAL TECHNOLOGY INC | $3,291 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-05-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-05-14 | Intuitive Surgical Operations, Inc. | $2,000 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion registry study and IRB fees | 2025 |
| 2025-05-12 | Abbott Laboratories | $14,363 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,022 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $4,067 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $2,272 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $2,175 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $1,917 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-06 | United Therapeutics Corporation | $2,655 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-05-06 | United Therapeutics Corporation | $100 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-05-02 | BeiGene, Ltd. | $78,790 | Research payment | Cash or cash equivalent | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac | 2025 | |
| 2025-05-02 | Alexion Pharmaceuticals, Inc. | $45 | Research payment | In-kind items and services | STRENSIQ Biological, Rare Disease | A Prospective Observational Sub Study of the Global Hypophosphatasia Registry to Evaluate the Potential Risk of Immune M | 2025 |
| 2025-04-30 | Jenavalve Technology, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | KARL STORZ Endoscopy-America | $750 | Grant | Cash or cash equivalent | C-MAC Device, ANESTHESIOLOGY | 2025 | |
| 2025-04-25 | National Marrow Donor Program | $12,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-24 | United Therapeutics Corporation | $1,300 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-04-24 | United Therapeutics Corporation | $1,000 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-04-24 | United Therapeutics Corporation | $650 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-04-24 | United Therapeutics Corporation | $500 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-04-23 | Novartis Pharmaceuticals Corporation | $24,162 | Research payment | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-04-23 | United Therapeutics Corporation | $2,698 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-04-23 | United Therapeutics Corporation | $1,468 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-04-10 | United Therapeutics Corporation | $750 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-04-10 | United Therapeutics Corporation | $282 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-04-10 | United Therapeutics Corporation | $253 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-04-10 | United Therapeutics Corporation | $189 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-04-10 | United Therapeutics Corporation | $75 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-04-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,738 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-04-09 | United Therapeutics Corporation | $2,802 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-04-09 | United Therapeutics Corporation | $2,635 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-04-09 | United Therapeutics Corporation | $1,336 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-04-09 | United Therapeutics Corporation | $864 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-04-08 | Abbott Laboratories | $21,500 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-04-08 | Boston Scientific Corporation | $4,485 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-04-07 | APPLIED MEDICAL TECHNOLOGY INC | $2,717 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-04-04 | United Therapeutics Corporation | $11,880 | Research payment | Cash or cash equivalent | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 | |
| 2025-04-03 | Organogenesis Inc. | $450 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PURAPLY WOUND MATRIX Device, WOUND CARE | 2025 | |
| 2025-03-25 | Boston Scientific Corporation | $3,005 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2025 |
| 2025-03-19 | Zimmer Biomet Holdings, Inc. | $740 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-03-17 | Abbott Laboratories | $15,869 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-03-12 | AstraZeneca Pharmaceuticals LP | $189,363 | Research payment | Cash or cash equivalent | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice N | 2025 | |
| 2025-03-12 | United Therapeutics Corporation | $135 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $830 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-03-10 | APPLIED MEDICAL TECHNOLOGY INC | $3,342 | Royalty or License | Cash or cash equivalent | AMT Bridle Device, Enteral | 2025 | |
| 2025-03-04 | United Therapeutics Corporation | $5,500 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
The latest 200 records of 244.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Provo, UT, county Utah County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Provo, UT | County Utah County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 114,766 | 705,400 | 3,392,331 |
| Population, 2020 census P1 | 115,162 | 659,399 | 3,271,616 |
| Median age B01002 | 23.6 | 25.8 | 32.0 |
| Under 18 B01001 | 18.7% | 31.6% | 27.8% |
| 65 and over B01001 | 6.7% | 7.9% | 11.9% |
| Households B11001 | 34,022 | 203,018 | 1,124,822 |
| Foreign born B05002 | 12.5% | 8.2% | 8.9% |
| Median household income B19013 | $64,171 | $100,671 | $95,166 |
| Median family income B19113 | $73,450 | $110,986 | $109,675 |
| Per capita income B19301 | $27,822 | $37,082 | $40,873 |
| Poverty rate B17001 | 23.0% | 8.7% | 8.5% |
| Unemployment rate B23025 | 5.1% | 3.8% | 3.6% |
| Civilian labor force B23025 | 69,670 | 363,771 | 1,778,106 |
| Mean commute (minutes) B08013 | 18.4 | 22.6 | 22.1 |
| Bachelor's degree or higher B15003 | 45.2% | 44.4% | 37.7% |
| Housing units B25001 | 35,944 | 211,066 | 1,223,468 |
| Owner-occupied B25003 | 39.4% | 68.3% | 70.2% |
| Renters B25003 | 60.6% | 31.7% | 29.8% |
| Median home value B25077 | $467,200 | $538,700 | $489,400 |
| Median gross rent B25064 | $1,193 | $1,541 | $1,496 |
| White, not Hispanic B03002 | 70.8% | 77.6% | 74.7% |
| Black B03002 | 1.1% | 0.7% | 1.1% |
| Hispanic or Latino B03002 | 19.2% | 14.5% | 15.9% |
| Asian B03002 | 2.2% | 1.5% | 2.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Provo, UT.
Comments